Blueprint Medicines Corporation (BPMC)
| Market Cap | 5.73B |
| Revenue (ttm) | 434.42M |
| Net Income (ttm) | -128.05M |
| Shares Out | 63.53M |
| EPS (ttm) | -2.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,267,436 |
| Open | 88.12 |
| Previous Close | 88.93 |
| Day's Range | 87.99 - 90.99 |
| 52-Week Range | 72.24 - 121.90 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | 120.79 (+34.0%) |
| Earnings Date | Feb 13, 2025 |
About BPMC
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medul... [Read more]
Financial Performance
In 2023, Blueprint Medicines's revenue was $249.38 million, an increase of 22.22% compared to the previous year's $204.04 million. Losses were -$506.98 million, -9.06% less than in 2022.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is $120.79, which is an increase of 34.00% from the latest price.
News
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 ...
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
-- ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM -- -- Bone density analyses reported in patients with advanced SM underscore disease-modif...
Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
Blueprint Medicines' core revenue driver, AYVAKIT, has gained traction in systemic mastocytosis and gastrointestinal stromal tumors, reflecting strong market adoption. The recent AYVAKIT expansion int...
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
JP Morgan initiated coverage on Blueprint Medicines Corporation BPMC, a biotech company focused on modulating immune mast cells.
Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief E...
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
-- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 -- -- On track to init...
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
CAMBRIDGE, Mass. , Oct. 16, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
The Schall Law Firm Has Launched An Inquiry Into Whether Blueprint Medicines Corporation Violated Securities Laws And Impacted Investors Are Invited To Join
LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Me...
Blueprint Medicines Corporation Is Being Investigated For Securities Fraud And Stakeholders With Losses Should Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Me...
Blueprint Medicines to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. , Sept. 10, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming virtual investor conferences: Stifel 2024 I...
The Schall Law Firm Invites Investors To Join An Inquiry Into Blueprint Medicines Corporation For Possibly Committing Securities Related Infractions
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Med...
Blueprint Medicines Corporation May Have Engaged In Securities Fraud And Shareholder Participation In An Investigation Is Encouraged By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Med...
The Schall Law Firm Is Looking Into Blueprint Medicines Corporation For Possible Securities Law Violations And Investors Are Urged To Join The Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Med...
Blueprint Medicines Corporation May Have Defrauded Shareholders And The Schall Law Firm Wants Those With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Med...
The Schall Law Firm Is Looking Into Blueprint Medicines Corporation For Potential Securities Law Violations And Investors Are Encouraged To Join
LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Med...
Blueprint Medicines Corporation May Have Defrauded The Public And The Schall Law Firm Seeks Shareholder Participation In An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Med...
The Schall Law Firm Is Looking Into Whether Blueprint Medicines Corporation Committed Securities Related Improprieties And Investors Should Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Med...
Shareholders Can Now Join The Schall Law Firm In Investigating Securities Related Infractions By Blueprint Medicines Corporation
LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Med...
The Schall Law Firm Is Looking Into Blueprint Medicines Corporation's Possible Securities Fraud And Investors Are Invited To Assist
LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medic...
Blueprint Medicines Corporation May Have Violated Securities Regulations And The Schall Law Firm Seeks Shareholders' Help In The Inquiry
LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medic...
Investors Are Encouraged To Contact The Schall Law Firm About An Investigation Into Blueprint Medicines Corporation's Securities Related Impropriety
LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medic...
Blueprint Medicines Corporation May Have Committed Securities Fraud And The Schall Law Firm Seeks Shareholders To Join An Inquiry
LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medic...
Investors Are Urged To Participate In An Investigation Into Blueprint Medicines Corporation's Potential Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medic...
Blueprint Medicines Corporation Is Being Looked Into For Possible Securities Fraud And The Schall Law Firm Invites Shareholders To Help
LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medic...
An Inquiry Has Been Launched Into Blueprint Medicines Corporation For Securities Law Violations And The Schall Law Firm Seeks Investor Involvement
LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medic...